// App-Quantinova.ai

BSH2020‐PO‐113 : Risk of pneumonia and tolerability in patients with multiple myeloma treated with daratumumab: a systematic review and combined meta‐ analysis of six phase III randomised controlled trials

Researchers

Presenter

  • T. W. Htut

Principal Investigators

  • K. Z. Thein

  • M. A. Win

  • E. M. Phyu

  • A. Lawrie

  • J. Tighe

  • G. Preston

Medical Centers

  • Department of Haematology, Aberdeen Royal Infirmary, Foresterhill Health Campus, Aberdeen, United Kingdom

  • Department of Investigational Cancer Therapeutics (Phase 1 Program), The University of Texas MD Anderson Cancer Center, Houston, TX

  • Internal Medicine, LewisGale Medical Center, Salem, VA, USA

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

  • Hematological malignancies

  • Solid malignancies

Biomarkers

  • Cluster of Differentiation 38

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Lenalidomide

  • Prednisolone

  • carfilzomib Intravenous

  • daratumumab Intravenous

  • Thalidomide

  • Bortezomib

  • Melphalan

Outcome

  • N/A

Study Design

  • Randomized

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved